DSM Pharmaceutical Products forms manufacturing alliance with Galenix

Published: 6-Nov-2009
Media Manufacturing Drug Delivery Pharmaceutical

US-based DSM Pharmaceutical Products has made a manufacturing alliance with Galenix, of Saint Jean D'Illac, France, whereby DSM will be the preferred commercial-scale manufacturing partner for Galenix commercial products on a global basis. No financial terms were disclosed.


US-based DSM Pharmaceutical Products has made a manufacturing alliance with Galenix, of Saint Jean D'Illac, France, whereby DSM will be the preferred commercial-scale manufacturing partner for Galenix commercial products on a global basis. No financial terms were disclosed.

The two companies will collaborate on business development opportunities co-marketing Galenix drug delivery technologies, based on the strength of Galenix in drug product development and clinical services and DSM in process development, scale-up and commercial-scale pharmaceutical manufacturing.

"These innovative drug delivery technologies enhance our offering in the field of pharmaceutical development services and complement our portfolio of drug delivery technologies," said Pieter de Geus, DSM Senior Vice President, r&d.

Jerome Besse, ceo of Galenix, concurred, adding: "The partnership fits with our strategic intention of expanding service offerings to the North America market, and also with DSM's expansion of sales & marketing focus in Europe."

  • Companies:
  • dsm-firmenich
See more

You may also like

Manufacturing

dsm-firmenich initiates patent infringement action

Read more
dsm-firmenich asserts that Shengda’s production of a key biotin intermediate at its Anhui site is an unlawful use of patented technology

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    How CDMOs can set a new gold standard when it comes to going green Sustainability is more than a feel-good initiative or a choice; it’s a strategic imperative. Not missing a beat, pharma companies have been making a concerted effort towards positive change, reports Tim Lowery, President of JSR Life Sciences and CEO, KBI Biopharma
  2. Mastering modified-release performance: excipient considerations Imagine a world where enhanced therapeutic efficacy, improved patient compliance and reduced adverse effects are tangible outcomes — even for drugs with short pharmacokinetic (PK) half-lives or narrow therapeutic indices. This is becoming a reality with modified-release (MR) oral delivery systems such as hydrophilic matrix tablets
  3. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Manufacturing

dsm-firmenich initiates patent infringement action

dsm-firmenich asserts that Shengda’s production of a key biotin intermediate at its Anhui site is an unlawful use of patented technology
Manufacturing

DSM and Chromatic 3D Materials partner

The global science-based company active in health, nutrition and materials, has entered a partnership with the 3D-printer developer to introduce thermoset materials for 3D-printing of finished manufactured goods
Media

Finished dosage formulation of Rosuvastatin successfully launched

DSM Sinochem Pharmaceutical (DSP) has successfully launched its fully backward integrated, generic Rosuvastatin drug product in multiple Western European countries, the launch will be extended to additional countries before the end of January
Manufacturing

DSM Sinochem to boost manufacturing capacity at Dutch plant

Increased production will meet growing demand for sustainable antibiotics, helping tackle Antimicrobial Resistance
Manufacturing

DSM Sinochem Pharmaceuticals celebrates 15 years of green 7-ADCA production

Saving more than lives alone
Infection Control

DSM Sinochem Pharmaceuticals wins European Responsible Care Award for work in sustainable antibiotics

Sustainable Antibiotics programme is DSP’s own initiative to promote the responsible manufacturing and use of antibiotics
Manufacturing

Update on SafeBridge potent compound safety certification programme

The programme provides drug innovators with an independent assessment of a manufacturing company’s ability to safely produce potent APIs and drug products
Subscribe now